Pancreatic Cancer Research

ResearcherNebraska Medical CenterActive in the last 2 years

Paul M. Grandgenett

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-6905-1805; OpenAlex author ID A5090202565; NIH RePORTER profile ID 8731990. Sources: OpenAlex.

Their work

Papers
48 (first author 3, last author 0)
Trials
0
Grants
2
Labs led
2
Collaborators
222
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 3 papers · 2014: none · 2015: 1 paper · 2016: 2 papers · 2017: 2 papers · 2018: 1 paper · 2019: 5 papers · 2020: 2 papers · 2021: 6 papers · 2022: 7 papers · 2023: none · 2024: 8 papers · 2025: 4 papers · 2026: 6 papers, 2 grants

Papers 48

  1. A MUC1-ALIX complex regulates extracellular vesicle cargo loading with activated SRC to enhance pancreatic cancer progression. Co-author DOI 10.1016/j.canlet.2026.218411↗
  2. The circadian gene Dec2 promotes pancreatic cancer progression and dormancy through immune evasion. Co-author DOI 10.1016/j.devcel.2026.04.001↗
  3. Differences in collagen structure and organization in primary and metastatic pancreatic cancer and the effects of FOLFIRINOX treatment. Co-author DOI 10.1016/j.mbplus.2026.100193↗
  4. Distinct glycosyltransferase expression governs organ-specific survival in pancreatic cancer metastasis. Co-author DOI 10.1038/s41388-026-03896-5↗
  5. Hepatocytes promote liver metastasis of pancreatic cancer by providing serine. Co-author DOI 10.1038/s41586-026-11051-z↗
  6. AI-Powered Deep Visual Proteomics Reveals Critical Molecular Transitions in Pancreatic Cancer Precursors. Co-author DOI 10.1158/2159-8290.cd-25-1119↗
  7. Co-treatment of ticagrelor and anti-PD-1 immunotherapy in tumor-associated macrophages reduces pancreatic cancer cell growth and migration through the TGF-β1/S… Co-author DOI 10.1016/j.biopha.2025.118695↗
  8. Spatial mapping of transcriptomic plasticity in metastatic pancreatic cancer. Co-author DOI 10.1038/s41586-025-08927-x↗
  9. Pancreatic cancer cachexia is mediated by PTHrP-driven disruption of adipose de novo lipogenesis Co-author DOI 10.1101/2025.06.03.657464↗
  10. Neutrophil Dynamics Contribute to Disease Progression and Poor Survival in Pancreatic Cancer. Co-author DOI 10.3390/cancers17213541↗
  11. Engrailed-1 Promotes Pancreatic Cancer Metastasis. Co-author DOI 10.1002/advs.202308537↗
  12. Single-cell RNA-sequencing of human spleens reveals an IDO-1+ tolerogenic dendritic cell subset in pancreatic cancer patients that is absent in normal individu… Co-author DOI 10.1016/j.canlet.2024.217321↗
  13. Coxsackievirus and adenovirus receptor expression facilitates enteroviral infections to drive the development of pancreatic cancer. Co-author DOI 10.1038/s41467-024-55043-x↗
  14. Cancer-associated fibroblast-derived acetate promotes pancreatic cancer development by altering polyamine metabolism via the ACSS2-SP1-SAT1 axis. Co-author DOI 10.1038/s41556-024-01372-4↗
  15. Author Correction: Cancer-associated fibroblast-derived acetate promotes pancreatic cancer development by altering polyamine metabolism via the ACSS2-SP1-SAT1 … Co-author DOI 10.1038/s41556-024-01417-8↗
  16. Multi-parametric atlas of the pre-metastatic liver for prediction of metastatic outcome in early-stage pancreatic cancer. Co-author DOI 10.1038/s41591-024-03075-7↗
  17. radioGWAS links radiome to genome to discover driver genes with somatic mutations for heterogeneous tumor image phenotype in pancreatic cancer. First author DOI 10.1038/s41598-024-62741-5↗
  18. Structural Basis for Multivalent MUC16 Recognition and Robust Anti-Pancreatic Cancer Activity of Humanized Antibody AR9.6. Co-author DOI 10.1158/1535-7163.mct-23-0868↗
  19. Methionine oxidation activates pyruvate kinase M2 to promote pancreatic cancer metastasis. Co-author DOI 10.1016/j.molcel.2022.06.005↗
  20. CD73 induces GM-CSF/MDSC-mediated suppression of T cells to accelerate pancreatic cancer pathogenesis. Co-author DOI 10.1038/s41388-021-02132-6↗
  21. Visceral adipose tissue remodeling in pancreatic ductal adenocarcinoma cachexia: the role of activin A signaling. Co-author DOI 10.1038/s41598-022-05660-7↗
  22. Mucin 5AC-Mediated CD44/ITGB1 Clustering Mobilizes Adipose-Derived Mesenchymal Stem Cells to Modulate Pancreatic Cancer Stromal Heterogeneity. Co-author DOI 10.1053/j.gastro.2022.02.032↗
  23. MUC16 Promotes Liver Metastasis of Pancreatic Ductal Adenocarcinoma by Upregulating NRP2-Associated Cell Adhesion. Co-author DOI 10.1158/1541-7786.mcr-21-0888↗
  24. Ubiquitous Aberration in Cholesterol Metabolism across Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/metabo12010047↗
  25. Differential expression profile of CXC-receptor-2 ligands as potential biomarkers in pancreatic ductal adenocarcinoma. Co-author PMID 35141005↗
  26. Isoforms of MUC16 activate oncogenic signaling through EGF receptors to enhance the progression of pancreatic cancer. Co-author DOI 10.1016/j.ymthe.2020.12.029↗
  27. Metabolic programming of distinct cancer stem cells promotes metastasis of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41388-020-01518-2↗
  28. Suppression of pancreatic cancer liver metastasis by secretion-deficient ITIH5. Co-author DOI 10.1038/s41416-020-01093-z↗
  29. Author Correction: Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring. Co-author DOI 10.1038/s41586-021-04176-w↗
  30. IgE-Based Therapeutic Combination Enhances Antitumor Response in Preclinical Models of Pancreatic Cancer. Co-author DOI 10.1158/1535-7163.mct-21-0368↗
  31. Plexin-B3 Regulates Cellular Motility, Invasiveness, and Metastasis in Pancreatic Cancer. Co-author DOI 10.3390/cancers13040818↗
  32. Macrophages potentiate STAT3 signaling in skeletal muscles and regulate pancreatic cancer cachexia. Co-author DOI 10.1016/j.canlet.2020.04.017↗
  33. The Proteomic Landscape of Pancreatic Ductal Adenocarcinoma Liver Metastases Identifies Molecular Subtypes and Associations with Clinical Response. Co-author DOI 10.1158/1078-0432.ccr-19-1496↗
  34. Trefoil factor(s) and CA19.9: A promising panel for early detection of pancreatic cancer. Co-author DOI 10.1016/j.ebiom.2019.03.056↗
  35. Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring. Co-author DOI 10.1038/s41586-019-1130-6↗
  36. Role of keratan sulfate expression in human pancreatic cancer malignancy. Co-author DOI 10.1038/s41598-019-46046-6↗
  37. Truncated O-glycans promote epithelial-to-mesenchymal transition and stemness properties of pancreatic cancer cells. Co-author DOI 10.1111/jcmm.14572↗
  38. Upregulation of ZIP14 and Altered Zinc Homeostasis in Muscles in Pancreatic Cancer Cachexia. Co-author DOI 10.3390/cancers12010003↗
  39. Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-18-0349↗
  40. MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer. Co-author DOI 10.1016/j.ccell.2017.06.004↗
  41. Enhancer Reprogramming Promotes Pancreatic Cancer Metastasis. Co-author DOI 10.1016/j.cell.2017.07.007↗
  42. Image-based detection and targeting of therapy resistance in pancreatic adenocarcinoma. Co-author DOI 10.1038/nature17988↗
  43. Identification of FRA-1 as a novel player in pancreatic cancer in cooperation with a MUC1: ERK signaling axis. Co-author DOI 10.18632/oncotarget.9557↗
  44. Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. Co-author DOI 10.1038/ncb3169↗
  45. Expression of core 3 synthase in human pancreatic cancer cells suppresses tumor growth and metastasis. First author DOI 10.1002/ijc.28322↗
  46. Rosiglitazone and Gemcitabine in combination reduces immune suppression and modulates T cell populations in pancreatic cancer. Co-author DOI 10.1007/s00262-012-1324-3↗
  47. MicroRNA-200c modulates the expression of MUC4 and MUC16 by directly targeting their coding sequences in human pancreatic cancer. Co-author DOI 10.1371/journal.pone.0073356↗
  48. Cyclin-dependent kinase 5 is amplified and overexpressed in pancreatic cancer and activated by mutant K-Ras. First author DOI 10.1158/1078-0432.ccr-10-2288↗

Grants 2

  1. Critical Resources Provided by UNMC Rapid Autopsy Program (RAP) Biorepository Stimulate Cancer Research R50CA211462↗
  2. MUC1 in Therapy Resistance U54CA274329↗

Closest collaborators

The 25 strongest of 222 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Michael Anthony Hollingsworth · 42 shared papers, 1 shared grant, 2011–2026 · strength 6.53
  2. Pankaj Kumar Singh · 9 shared papers, 1 shared grant, 2011–2026 · strength 1.91
  3. Thomas C. Caffrey · 12 shared papers, 2011–2026 · strength 1.56
  4. Surinder K. Batra · 10 shared papers, 2013–2026 · strength 1.18
  5. Jean L. Grem · 8 shared papers, 2017–2026 · strength 1.04
  6. Jixin Dong · 1 shared grant, 2026 · strength 0.86
  7. Surendra Kumar Shukla · 7 shared papers, 2017–2024 · strength 0.77
  8. Kamiya Mehla · 6 shared papers, 2017–2024 · strength 0.71
  9. Prakash Radhakrishnan · 7 shared papers, 2013–2024 · strength 0.67
  10. Kavita B. Mallya · 5 shared papers, 2015–2026 · strength 0.62
  11. Jesse L. Cox · 3 shared papers, 2022–2026 · strength 0.57
  12. Aneesha Dasgupta · 5 shared papers, 2017–2024 · strength 0.55
  13. Ryan J. King · 5 shared papers, 2017–2024 · strength 0.55
  14. Kuldeep Singh Attri · 5 shared papers, 2017–2024 · strength 0.55
  15. Koelina Ganguly · 3 shared papers, 2019–2026 · strength 0.48
  16. Pranita Atri · 4 shared papers, 2019–2022 · strength 0.48
  17. Satyanarayana Rachagani · 4 shared papers, 2019–2022 · strength 0.45
  18. Sanchita Rauth · 3 shared papers, 2021–2026 · strength 0.45
  19. Saravanakumar Marimuthu · 3 shared papers, 2021–2026 · strength 0.45
  20. Moorthy Palanimuthu Ponnusamy · 3 shared papers, 2021–2026 · strength 0.45
  21. Divya Murthy · 4 shared papers, 2017–2024 · strength 0.44
  22. Nina V. Chaika · 4 shared papers, 2017–2024 · strength 0.44
  23. Kyle L. McAndrews · 2 shared papers, 2024–2026 · strength 0.43
  24. Clara S. Mundry · 2 shared papers, 2024–2026 · strength 0.43
  25. Caitlin Molczyk · 2 shared papers, 2022–2025 · strength 0.42

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.